WHO has published a global TB report every year since 1997. This 2018 edition is published in the lead up to the UN high-level meeting on TB. It provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in the response to the epidemic, at global, regional and country levels. The report is based primarily on data reported annually to WHO by countries, and databases maintained by other UN agencies and the World Bank.
Worldwide, TB is one of the top 10 causes of death and the leading cause from a single infectious agent (above HIV/AIDS). Millions of people continue to fall sick with TB each year.
The Challenging Operating Environments (COEs) Policy aims to provide a standard approach for the Global Fund in places where it can be difficult to work. The main aims of the policy are to promote creative ideas in difficult situations (innovation), increased flexibility in places that are going through difficult circumstances, and partnerships with local country actors.
MSF’s report explores the causes of the treatment gap in a vast region comprising 25 countries, with detailed case studies on three contexts: Central African Republic, Democratic Republic of Congo and Guinea. MSF’s report finds that in West and Central Africa needs are underestimated and little priority is given to HIV as a health issue in the region. The route to obtaining HIV treatment is an obstacle course for people living with HIV with barriers such as stigma, stock outs of diagnostics and drugs, patient fees, and unaffordable, burdensome and poor quality services. Recurrent crises following violence or epidemics compound already existing challenges to accessing HIV care. The report recommends major changes in policies and models of care reflecting both lessons learned from progress in the fight against HIV elsewhere as well as innovative approaches specially tailored to contexts with low ART coverage.
The affordability, availability, and financing of medicines and other health commodities has always been a central issue for the Global Fund to Fight AIDS, Tuberculosis, and Malaria, its donors, recipient countries, and affected communities. Given the significant amount and proportion of Global Fund grant funding that goes to health commodities procurement, the strategic and operational components of their procurement and price strategies, and the availability of suppliers and access to their products, are key to ensuring availability and affordability of medicines.
Current and proposed policies have created a growing concern that the Global Fund is fundamentally altering its approach to access to medicines. There appears to be a progressive rollback of its previous position of...
This report reflects on the founding values of the Global Fund, where it has made progress and where it has fallen short. It outlines three critical areas that require attention and advocacy:
realizing the Global Fund’s human rights objectives
preserving support in middle income countries
supporting access to medicines for all at the lowest possible price
A period of changing global health governance and a dramatically shifting geography of poverty are part of the context for this briefing paper’s consideration of the impact of changes at the Global Fund to Fight AIDS, TB, and Malaria, including the Fund’s so-called New Funding Model.
This report is a resource for advocates working to assess the impact of the New Funding Model and to help shape the next five-year strategy.
Publisher: All-Party Parliamentary Group on HIV and AIDS
This report is the product of an almost year-long inquiry into the availability and affordability of drugs and diagnostics across the developing world. According to the All-Party Parliamentary Group on HIV and AIDS, despite notable success in the global AIDS response, access to medicines is threatened by withdrawal of funding in middle-income countries, the imposition of ever stricter rules on intellectual property, a failure to reach key population groups like LGBT people, sex workers and people who inject drugs, and insufficient R&D for child-friendly anti-retrovirals and treatments for HIV co-infections like TB.
Access Denied report calls for:
Review of funding decisions affecting middle income countries
Global Fund leadership on Hepatitis C treatment
Action to support use of TRIPS flexibilities to overcome high medicine prices
Review of patent-ba...
This entry was posted in and tagged treatment access on by admin.